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Background:  Percutaneous treatment of saphenous vein graft disease is associated with high rates of periprocedural myocardial infarction (MI). 
The use of embolic protection (EPD) devices during these interventions is recommended when technically feasible, yet they are used routinely in less 
than half of all cases. Anecdotally, we have noticed similar findings of EPD under-utilization and wanted to explore whether or not this practice led to 
any untoward cardiovascular events.
Methods:  Consecutive vein graft interventions from 2003-2008 were identified and stratified by EPD use. Information pertaining to demographics, 
comorbidities, medication use, and procedural details was collected. Endpoints of interest included periprocedural MI defined as any creatinine 
kinase-MB fraction elevation greater than three times the upper limit of normal, and the composite of all cause death, MI, or target vessel 
revascularization (TVR) at one year. Categorical variables were analyzed using Fisher’s test; continuous variables were analyzed with t-testing. 
Multivariate logistic regression analysis was employed to assess for independent predictors of periprocedural MI.
Results:  One hundred sixty four (164) vein graft interventions were identified and EPDs were used in 71 cases (43.4%). Periprocedural MI 
occurred in 22 cases; 12 in the non-EPD group and 10 in the EPD group (14.1 vs. 12.9%, p=0.82). The composite endpoint of death, MI, or TVR was 
significantly lower when EPDs were used (11.3 vs. 25.8%, p=0.03). Chronic kidney disease increased the risk of periprocedural MI 8 times (OR 8.05, 
95% CI 2.71 to 23.89), whereas the use of beta blockers and long acting nitrates were protective (OR 0.20, 95% CI 0.06 to 0.67 and OR 0.26, 95% 
CI 0.07 to 0.93, respectively).
Conclusions:  EPD use during vein graft interventions did not improve periprocedural MI rates, though adverse cardiovascular outcomes at 1 year 
were significantly reduced. EPDs are used in a minority of vein graft interventions. Efforts aimed at improving adherence to EPD use may improve 
long-term outcomes, though this hypothesis should be tested using prospective, randomized studies.
